Surgalign announced that the United States Patent and Trademark Office recently issued a patent covering a machine learning system for automated segmentation of a three-dimensional bony structure in a medical image. The granted patent expands and further strengthens the company’s HOLO AI technology portfolio.
Surgalign is committed to applying its HOLO AI portfolio to help improve patient outcomes across the continuum of care, and continues to advance its clinical development and commercialization strategy. The first applications are intended for the U.S. where more than 1.5 million instrumented spinal procedures are performed each year.
“This patent is a foundational element of how we harness technology and data to power our digital surgery platform,” said Terry Rich, Surgalign’s president and chief executive officer. “While ‘artificial intelligence’ and ‘machine learning’ have become buzzwords that are often misused, misrepresented, and misunderstood, at Surgalign AI is a core competency and a key element of our efficient and highly valuable approach to improving patient’s lives.”
“This machine learning based approach is key for teaching the computer anatomy,” said Dr. Kris Siemionow, MD, PhD and Surgalign’s Chief Medical Officer. “This has created an opportunity for us to develop a variety of applications in which AI can assist the physician both inside and outside of the operating room.”
Surgalign announced that the United States Patent and Trademark Office recently issued a patent covering a machine learning system for automated segmentation of a three-dimensional bony structure in a medical image. The granted patent expands and further strengthens the company’s HOLO AI technology portfolio.
Surgalign is committed to applying...
Surgalign announced that the United States Patent and Trademark Office recently issued a patent covering a machine learning system for automated segmentation of a three-dimensional bony structure in a medical image. The granted patent expands and further strengthens the company’s HOLO AI technology portfolio.
Surgalign is committed to applying its HOLO AI portfolio to help improve patient outcomes across the continuum of care, and continues to advance its clinical development and commercialization strategy. The first applications are intended for the U.S. where more than 1.5 million instrumented spinal procedures are performed each year.
“This patent is a foundational element of how we harness technology and data to power our digital surgery platform,” said Terry Rich, Surgalign’s president and chief executive officer. “While ‘artificial intelligence’ and ‘machine learning’ have become buzzwords that are often misused, misrepresented, and misunderstood, at Surgalign AI is a core competency and a key element of our efficient and highly valuable approach to improving patient’s lives.”
“This machine learning based approach is key for teaching the computer anatomy,” said Dr. Kris Siemionow, MD, PhD and Surgalign’s Chief Medical Officer. “This has created an opportunity for us to develop a variety of applications in which AI can assist the physician both inside and outside of the operating room.”
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
